Hydroxyurea treatment in patients affected with sickle cell anemia: Efficacy and safety;Traitement des patients drépanocytaires par hydroxyurée : efficacité et tolérance

Transfusion Clinique et Biologique

Volumn 15, Issue 1-2, 2008, Pages 34-38

  de Montalembert, M ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Acute chest syndrome; Hydroxyurea; Pain; Sickle cell disease

Indexed keywords

HYDROXYUREA;

ACUTE CHEST SYNDROME; ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; AZOOSPERMIA; BONE MARROW SUPPRESSION; BREAST CANCER; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; HEADACHE; HUMAN; LONG TERM CARE; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NEUTROPENIA; OPPORTUNISTIC INFECTION; OUTCOME ASSESSMENT; PANCYTOPENIA; SICKLE CELL ANEMIA; SPERMATOZOON ABNORMALITY; TESTIS CANCER; THROMBOCYTOPENIA; VERTIGO;

ANEMIA, SICKLE CELL; CONTROLLED CLINICAL TRIALS AS TOPIC; DRUG TOXICITY; HUMANS; HYDROXYUREA; MULTICENTER STUDIES AS TOPIC; TREATMENT OUTCOME;

EID: 49949151943     PISSN: 12467820     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tracli.2008.03.010     Document Type: Article

References (43)

1. Rogers Z.R., Lieff S., McMurray M., Dampier C., Wang W.C., Chelednik M., et al. Collaborative data project [C-DATA] of the comprehensive sickle cell centers program. Blood 108 (2006) 353a
2. Charache S., Terrin M.L., Moore R.D., Dover G.J., Barton F.B., Eckert S.V., et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. N Engl J Med 332 (1995) 1317-1322
3. Ferster A., Vermylen C., Cornu G., Buyse M., Corazza F., Devalck C., et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood 88 (1996) 1960-1964
4. Davies SC, Olyjohungbe A. Hydroxyurea for sickle cell disease (Cochrane review). In: the Cochrane Library, Issue 3, 2002, Update Software, Oxford.
5. Kutlar A., Woods K.F., Clair B., Daitch L., Milner P.F., Samuels B.J., et al. Long-term use of hydroxyurea (HU) in adults with sickle cell disease (SS): a large single center experience. Blood 96 (2000) 10a
6. Voskaridou E., Kalotychou V., and Loukopoulos D. Clinical and laboratory effects of long-term administration of hydroxyurea to patients with sickle-cell/beta-thalassaemia. Br J Haematol 89 (1995) 479-485
7. Rigano P., Rodgers G.P., Renda M.C., Aquino A., and Maggio A. Clinical and hematological responses to hydroxyurea in Sicilian patients with HbS/β-thalassemia. Hemoglobin 25 (2001) 9-17
8. Jayabose S., Tugal O., Sandoval C., Patel P., Puder D., Lin T., et al. Clinical and haematological effects of hydroxyurea in children with sickle cell disease. J Pediatr 129 (1996) 559-565
9. Scott J.P., Hillery C.A., Brown E.R., Misiewicz V., and Labotka R.J. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr 128 (1996) 820-828
10. Kinney T.R., Helms R.W., O'Branski E.E., Ohene-Frempong K., Wang W.C., Daeschner C., et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phaseI/II trial. Blood 94 (1999) 1550-1554
11. De Montalembert M., Bégué P., Bernaudin F., Thuret I., Bachir D., and Micheau M. Preliminary report of a toxicity study of hydroxyurea in sickle cell disease. Arch Dis Child 81 (1999) 437-439
12. Hoppe C., Vichinsky E., Quirolo K., Van Warmedam J., Allen K., and Styles L. Use of hydroxyurea in children aged 2 to 5 years with sickle cell disease. J Pediatr Hematol Oncol 22 (2000) 330-334
13. Wang W.C., Wynn L.W., Rogers Z.R., Scott J.P., Lane P.A., and Ware R.E. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr 139 (2001) 790-796
14. Steinberg M.H., Barton F., Castro O., Pegelow C.H., Ballas S.K., Kutlar A., et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. Risk and benefits up to nine years of treatment. JAMA 289 (2003) 1645-1651
15. Ferster A., Tahriri P., Vermylen C., Sturbois G., Corazza F., Fondu P., et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood 97 (2001) 3628-3632
16. Hankins J.S., Ware R.E., Rogers Z.R., Wynn L.W., Scott J.P., and Wang W.C. Long-term hydroxyurea therapy for infants with sickle cell anemia: the Husoft extension study. Blood 106 (2005) 2269-2275
17. Gulbis B., Haberman D., Dufour D., Christophe C., Vermylen C., Kagambega F., et al. Hydroxyurea for sickle cell disease in children and for prevention of cerebrovascular events. The Belgian experience. Blood 105 (2005) 2685-2690
18. Zimmerman S.A., Schultz W.H., Davis J.S., Pickens C.V., Mortier N.A., Howard T.A., et al. Sustained long-term efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 103 (2004) 2039-2045
19. Steinberg M.H., Lu Z.H., Barton F.B., Terrin M.L., Charache S., Dover G.J., et al. Fetal haemoglobin in sickle cell anemia: determinants of response to hydroxyurea. Blood 89 (1997) 1078-1088
20. Maier-Redelsperger M., de Montalembert M., Flahaut A., Neonato M.G., Ducrocq R., Masson M.P., et al. Fetal hemoglobin and F-cell response to long-term hydroxyurea treatment in young sickle cell patients. Blood 91 (1998) 4472-4479
21. Ware R.E., Eggleston B., Redding-Lallinger R., Wang W.C., Smith-Whitley K., Daescher C., et al. Predictors of fetal haemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood 99 (2002) 10-14
22. de Montalembert M., Bachir D., Hulin A., Gimeno L., Mogenet A., Bresson J.L., et al. Pharmacokinetics of the 1000 mg coated breakable tablets and 500 mg capsules in pediatric and adults with sickle cell disease. Haematologica 91 (2006) 1685-1688
23. Wyszynski D.F., Baldwin C.T., Cleves M.A., Farrell J.J., Bisbee A., Kutlar A., et al. Genetic polymorphisms associated with fetal haemoglobin response to hydroxyurea in patients with sickle cell anemia. Blood 104 (2004) 34a
24. Vichinsky E.P., and Lubin B.H. A cautionary note regarding hydroxyura in sickle cell disease. Blood 83 (1994) 1124-1128
25. Venigalla P., Motwani B., Nallari A., Allen S., Agarwal M., Alva M., et al. A patient on hydroxyurea for sickle cell disease who developed an opportunistic infection. Blood 100 (2002) 363-364
26. De Montalembert M., Brousse V., Elie C., Bernaudin F., Shi J., and Landais P. Long-term hydroxyurea treatment in children with sickle cell disease: tolerance and clinical outcomes. Haematologica 91 (2006) 125-128
27. O'Branski E.E., Ware R.E., Prose N.S., and Kinney T.R. Skin and nail changes in children with sickle cell disease receiving hydroxyurea therapy. J Am Acad Dermatol 44 (2001) 859-861
28. Chaine B., Neonato M.G., Girot R., and Aractingi S. Cutaneous adverse reaction to hydroxyurea in patients with sickle cell disease. Arch Dermatol 137 (2001) 467-470
29. Grigg A. Effect of hydroxyurea on sperm count, motility and morphology in sickle cell disease or myeloproliferative disease. Intern Med J 37 (2007) 190-192
30. Spencer F., Chi L., and Zhu M.X. Hydroxyurea inhibition of cellular and developmental activities in the decidualized and pregnant uteri of rats. J Appl Toxicol 20 (2000) 407-412
31. Wang W.C., Helms R.W., Lynn H.S., Redding-Lallinger R., Gee B., Ohene-Frempong K., et al. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS study. J Pediatr 140 (2002) 225-229
32. Bennett T., Bal H., Chen Q., Abdulmalik O., Yang J., Iyamu E., et al. Effects of orally-administered hydroxyurea on infant mice. Blood 102 (2003) 761a
33. Claster S., and Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood 88 (1996) 1951-1953
34. Santos A., Pinheiro V., Anjos C., Brandelise S., Fahel F., Lima M., et al. Scintigraphic follow-up of the effects of therapy with hydroxyurea on splenic function in patients with sickle cell disease. Eur J Nucl Med Mol Imaging 29 (2002) 536-541
35. Rauch A., Borromeo M., Ghafoor A., Khoyratty B., and Maheshwari J. Leukemogenesis of hydroxyurea in the treatment of sickle cell anemia. Blood 84 (1999) 415a
36. Wilson S. Acute leukaemia in a patient with sickle cell anemia treated with hydroxyurea. Ann Intern Med 133 (2000) 925-926
37. Moschovi M., Psychou F., Memegas D., Tsangari G.T., Tzortzatou-Stathopoulou F., and Nikolaidou P. Hodgkin's disease in a child with sickle cell disease treated with hydroxyurea. Pediatr Hematol Oncol 18 (2001) 371-376
38. Ferster A., Sariban E., and Meulemann N. Malignancies in sickle cell disease patients treated with hydroxyurea. Br J Haematol 123 (2003) 368-369
39. Schultz W.H., and Ware R.E. Malignancy in patients with sickle cell disease. Am J Hematol 74 (2003) 249-253
40. Hanft V.N., Fruchtman S.R., Pickens C.V., Rosse W.F., Howard T.A., and Ware R.E. Acquired DNA mutations associated with in vitro and in vivo hydroxyurea exposure. Blood 95 (2000) 3589-3593
41. Little J.A., McGowan V.R., Kato G.J., Partovi K.S., Feld J.J., Maric I., et al. Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica 91 (2006) 1076-1083
42. Ware R.E., Zimmerman S.A., Sylvestre P.B., Mortier N.A., Davis J.S., Treem W.R., et al. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy. J Pediatr 145 (2004) 346-352
43. Bakanay S.M., Dainer A., Clai B., Adekile A., Daitch L., Wells L., et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood 105 (2005) 545-547